Pendal Group LTD Amgen Inc Transaction History

Pendal Group LTD

$12.2 Billion
Q4 2022

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Jul 25, 2022	BUY	$230.71 - $256.74 $1.52 Million - $1.7 Million	6,609 New	6,609 $1.61 Million
Q1 2022 Apr 25, 2022	SELL	$219.27 - $242.57 $1.45 Million - $1.6 Million	-6,608 Closed	0 $0
Q4 2021 Jan 18, 2022	BUY	$198.88 - $227.6 $1.31 Million - $1.5 Million	6,608 New	6,608 $1.49 Million
Q1 2021 May 03, 2021	SELL	$221.91 - $258.6 $217,471 - $253,428	-980 Closed	0 $0
Q4 2020 Jan 21, 2021	BUY	$216.38 - $257.67 $212,052 - $252,516	980 New	980 $225,000
Q2 2020 Aug 07, 2020	SELL	$197.81 - $242.74 $2.7 Million - $3.31 Million	-13,641 Closed	0 $0
Q1 2020 May 04, 2020	BUY	$182.24 - $241.7 $2.42 Million - $3.21 Million	13,301 Added 3912.06%	13,641 $2.77 Million
Q4 2019 Feb 06, 2020	BUY	$189.21 - $243.2 $64,331 - $82,688	340 New	340 $81,000
Q3 2019 Nov 12, 2019	SELL	$174.11 - $208.62 $83,746 - $100,346	-481 Closed	0 $0
Q2 2019 Aug 01, 2019	BUY	$166.7 - $195.41 $80,182 - $93,992	481 New	481 $0
Q1 2019 May 01, 2019	SELL	$180.87 - $203.88 $2.64 Million - $2.97 Million	-14,587 Closed	0 $0
Q3 2018 Nov 05, 2018	SELL	$185.29 - $208.89 $642,029 - $723,803	-3,465 Reduced 19.19%	14,587 $0
Q2 2018 Jul 18, 2018	SELL	$166.05 - $186.51 $1.58 Million - $1.77 Million	-9,509 Reduced 34.5%	18,052 $0
Q1 2018 May 08, 2018	SELL	$169.43 - $198.0 $10.4 Million - $12.1 Million	-61,288 Reduced 68.98%	27,561 $0
Q4 2017 Feb 06, 2018	BUY	$168.79 - $188.59 $837,535 - $935,783	4,962 Added 5.92%	88,849 $0
Q3 2017 Nov 01, 2017	BUY	$167.29 - $191.0 $2.42 Million - $2.76 Million	14,447 Added 20.81%	83,887 $0
Q2 2017 Aug 11, 2017	BUY	N/A	69,440	69,440 $0

Others Institutions Holding AMGN

# of Institutions

3,121

Shares Held

410M

Call Options Held

7.56M

Put Options Held

7.2M

View Full List

About AMGEN INC

Ticker AMGN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 534,931,008
Market Cap $154B
Description
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...

More about AMGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Pendal Group LTD, based on Form 13F filings with the SEC.

News

Stay updated on Pendal Group LTD with notifications on news.

Account